APA (7th ed.) Citation

Mizrak Kaya, D., Ma, Y., Demir, T., Altomare, N. J., Kalyan, A., Kircher, S., . . . Mahalingam, D. (2026). KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials. Cancers, 18(13), 2037. https://doi.org/10.3390/cancers18132037

Chicago Style (17th ed.) Citation

Mizrak Kaya, Dilsa, et al. "KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials." Cancers 18, no. 13 (2026): 2037. https://doi.org/10.3390/cancers18132037.

MLA (9th ed.) Citation

Mizrak Kaya, Dilsa, et al. "KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials." Cancers, vol. 18, no. 13, 2026, p. 2037, https://doi.org/10.3390/cancers18132037.